Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Advances in Vaccine Development and Immunotherapies"
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (10 March 2021) | Viewed by 62945
Special Issue Editors
2. Department of Medicine, University of Oklahoma, Oklahoma, OK 73126, USA
Interests: immunotherapy; CAR-T cells; tumor microenvironment; checkpoint protein; hypoxia; tumor survival signaling
Special Issues, Collections and Topics in MDPI journals
Special Issue in Cancers: Cancer Stem Cells and Tumor Microenvironment
Special Issue in Cancers: Cancer Immunotherapies
Special Issue in Cancers: CAR-T Cell Therapy against Different Types of Cancer
Special Issue in Cancers: CAR-T Cell Therapy-Novel Approaches and Challenges
Special Issue in Cancers: Immunotherapy, Tumor Microenvironment and Survival Signaling
Special Issue in Cancers: Cell Therapy, Bispecific Antibodies and other Immunotherapies Against Cancer
Assistant Guest Editor
Interests: autophagy; Ubiquitin-Proteosome system; gene transcription; cell signaling; influenza virus; dengue virus; program cell death; epigenetics; drug discovery and development; chemical biology
Special Issue Information
During Covid-19 pandemic, it is very important to submit reports on vaccine development. Vaccine development can include vaccines against viral diseases, dendritic cell vaccines against cancer or other diseases. In addition, this issue can involve recent development of new immunotherapies against cancer such as chimeric antigen receptor (CAR) T cells therapies, checkpoint inhibitors, monoclonal antibodies, bi-specific antibodies, and combination therapies. The reports on pre-clinical vaccine development, clinical trial data and reviews can be submitted to this issue.
Dr. Vita Golubovskaya
Dr. Emmanuel Datan
Assistant Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.